LENZ Therapeutics Inc
LENZ14.220USD
+0.250+1.79%
Handelsschluss 02/06, 16:00（ET）Kurse um 15 Minuten verzögert
406.53MMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über LENZ Therapeutics Inc Unternehmen
LENZ Therapeutics, Inc. is a pre-commercial stage biopharmaceutical company. The Company is focused on the development and commercialization of aceclidine-based eye drop to improve near vision in patients with presbyopia. The Company’s lead product candidate LNZ100 is a preservative-free, single-use, once-daily eye drop containing aceclidine. LNZ100 was evaluated in the registration-enabling Phase III CLARITY study as a potential therapy for the treatment of presbyopia, a condition impacting over 1.8 billion people globally and 128 million people in the United States. Its other product LNZ101, is a preservative-free eye drop containing aceclidine and brimonidine.
LENZ Therapeutics Inc Informationen
BörsenkürzelLENZ
Name des UnternehmensLENZ Therapeutics Inc
IPO-datumJun 25, 2021
CEOSchimmelpennink (Evert)
Anzahl der mitarbeiter42
WertpapierartOrdinary Share
GeschäftsjahresendeJun 25
Addresse- -
Stadt- -
BörseNASDAQ OMX - NASDAQ BASIC
Land- -
Postleitzahl- -
Telefon- -
Website- -
BörsenkürzelLENZ
IPO-datumJun 25, 2021
CEOSchimmelpennink (Evert)
Führungskräfte von LENZ Therapeutics Inc
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. James Mccollum
Mr. James Mccollum
Independent Director
Independent Director
631.10K
+10500.00%
Mr. Marc Odrich
Mr. Marc Odrich
Chief Medical Officer
Chief Medical Officer
99.60K
--
Dr. Daniel R. (Dan) Chevallard
Dr. Daniel R. (Dan) Chevallard
Chief Financial Officer
Chief Financial Officer
5.39K
+2198.00%
Mr. Shawn Olsson
Mr. Shawn Olsson
Chief Commercial Officer
Chief Commercial Officer
4.73K
--
Ms. Kimberlee Cobleigh (Kim) Drapkin, CPA
Ms. Kimberlee Cobleigh (Kim) Drapkin, CPA
Independent Director
Independent Director
--
--
Mr. Evert (Eef) Schimmelpennink
Mr. Evert (Eef) Schimmelpennink
President, Chief Executive Officer, Secretary, Director
President, Chief Executive Officer, Secretary, Director
--
--
Dr. Frederic (Fred) Guerard, Pharm.D.
Dr. Frederic (Fred) Guerard, Pharm.D.
Independent Director
Independent Director
--
--
Jeff W. George
Jeff W. George
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Ms. Shelley B. Thunen
Ms. Shelley B. Thunen
Independent Director
Independent Director
--
--
Dr. Zachary (Zach) Scheiner, Ph.D.
Dr. Zachary (Zach) Scheiner, Ph.D.
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. James Mccollum
Mr. James Mccollum
Independent Director
Independent Director
631.10K
+10500.00%
Mr. Marc Odrich
Mr. Marc Odrich
Chief Medical Officer
Chief Medical Officer
99.60K
--
Dr. Daniel R. (Dan) Chevallard
Dr. Daniel R. (Dan) Chevallard
Chief Financial Officer
Chief Financial Officer
5.39K
+2198.00%
Mr. Shawn Olsson
Mr. Shawn Olsson
Chief Commercial Officer
Chief Commercial Officer
4.73K
--
Ms. Kimberlee Cobleigh (Kim) Drapkin, CPA
Ms. Kimberlee Cobleigh (Kim) Drapkin, CPA
Independent Director
Independent Director
--
--
Mr. Evert (Eef) Schimmelpennink
Mr. Evert (Eef) Schimmelpennink
President, Chief Executive Officer, Secretary, Director
President, Chief Executive Officer, Secretary, Director
--
--
Umsatzaufteilung
Relevante Daten wurden vom Unternehmen noch nicht offengelegt.
Relevante Daten wurden vom Unternehmen noch nicht offengelegt.
Nach Geschäftsbereich
Nach Region
Relevante Daten wurden vom Unternehmen noch nicht offengelegt.
Aktionärsstatistik
Aktualisiert: Sun, Feb 1
Aktualisiert: Sun, Feb 1
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
RA Capital Management, LP
13.36%
Alpha Wave Global, LP
11.54%
Versant Ventures
8.49%
Ridgeback Capital Management, L.P.
6.24%
UBS Financial Services, Inc.
5.02%
Andere
55.35%
Aktionäre
Aktionäre
Anteil
RA Capital Management, LP
13.36%
Alpha Wave Global, LP
11.54%
Versant Ventures
8.49%
Ridgeback Capital Management, L.P.
6.24%
UBS Financial Services, Inc.
5.02%
Andere
55.35%
Aktionärstypen
Aktionäre
Anteil
Venture Capital
34.63%
Investment Advisor
30.67%
Hedge Fund
23.82%
Investment Advisor/Hedge Fund
17.10%
Individual Investor
2.52%
Research Firm
2.00%
Pension Fund
0.23%
Bank and Trust
0.13%
Insurance Company
0.02%
Institutionelle Beteiligung
Aktualisiert: Thu, Jan 1
Aktualisiert: Thu, Jan 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q4
308
33.89M
108.31%
+1.02M
2025Q3
267
30.95M
100.67%
+981.38K
2025Q2
245
29.52M
104.44%
-639.13K
2025Q1
245
28.95M
104.22%
-285.84K
2024Q4
225
27.65M
100.55%
-350.42K
2024Q3
204
26.43M
96.17%
-1.73M
2024Q2
197
25.06M
103.06%
+4.18M
2024Q1
204
22.41M
93.92%
+12.70M
2023Q4
200
7.73M
92.24%
-2.14M
2023Q3
200
7.54M
90.13%
-2.49M
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
RA Capital Management, LP
4.18M
14.65%
--
--
Jun 30, 2025
Alpha Wave Global, LP
3.61M
12.66%
--
--
Jun 30, 2025
Versant Ventures
2.88M
10.1%
-135.30K
-4.48%
Sep 18, 2025
Ridgeback Capital Management, L.P.
1.95M
6.84%
--
--
Apr 14, 2025
UBS Financial Services, Inc.
881.48K
3.09%
+214.32K
+32.12%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
1.27M
4.44%
+216.45K
+20.60%
Jun 30, 2025
The Vanguard Group, Inc.
1.29M
4.52%
+91.53K
+7.65%
Jun 30, 2025
Paradigm BioCapital Advisors LP
1.72M
6.02%
+297.23K
+20.93%
Jun 30, 2025
72 Investment Holdings, LLC
1.02M
3.57%
--
--
Jun 30, 2025
Tang Capital Management, LLC
897.62K
3.15%
+130.68K
+17.04%
Jun 30, 2025
Mehr Anzeigen
Verbundene ETFs
Aktualisiert: Sat, Dec 6
Aktualisiert: Sat, Dec 6
Name
Anteil
State Street SPDR S&P Pharmaceuticals ETF
1.18%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
1.04%
Virtus LifeSci Biotech Clinical Trials ETF
0.68%
Invesco Dorsey Wright Healthcare Momentum ETF
0.44%
Invesco Dorsey Wright SmallCap Momentum ETF
0.27%
iShares U.S. Pharmaceuticals ETF
0.22%
ProShares Ultra Nasdaq Biotechnology
0.11%
iShares Micro-Cap ETF
0.09%
Invesco Nasdaq Biotechnology ETF
0.08%
iShares Biotechnology ETF
0.06%
Mehr Anzeigen
State Street SPDR S&P Pharmaceuticals ETF
Anteil1.18%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
Anteil1.04%
Virtus LifeSci Biotech Clinical Trials ETF
Anteil0.68%
Invesco Dorsey Wright Healthcare Momentum ETF
Anteil0.44%
Invesco Dorsey Wright SmallCap Momentum ETF
Anteil0.27%
iShares U.S. Pharmaceuticals ETF
Anteil0.22%
ProShares Ultra Nasdaq Biotechnology
Anteil0.11%
iShares Micro-Cap ETF
Anteil0.09%
Invesco Nasdaq Biotechnology ETF
Anteil0.08%
iShares Biotechnology ETF
Anteil0.06%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Ex-Dividendentag
Art
Verhältnis
Mar 19, 2024
Merger
7→1
Mar 19, 2024
Merger
7→1
Mar 19, 2024
Merger
7→1
Mar 19, 2024
Merger
7→1
Datum
Ex-Dividendentag
Art
Verhältnis
Mar 19, 2024
Merger
7→1
Mar 19, 2024
Merger
7→1
Mar 19, 2024
Merger
7→1
Mar 19, 2024
Merger
7→1
